Novartis Gets FDA Breakthrough Therapy Designation for Scemblix
By Pierre Bertrand
Novartis said the U.S. drug regulator decided to expedite the development of Scemblix, to treat adults newly diagnosed with leukemia.
The Swiss pharmaceutical company said the U.S. Food and Drug Administration designated the treatment as a breakthrough therapy for the third time.
Drugs that get designated as breakthrough therapies are those designed to treat serious conditions and that have shown "that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s)," according to the FDA's website.
This latest designation was based off of the Phase III ASC4FIRST study, in which the drug met both of its primary endpoints, the company said.
Novartis will present the full findings of the study at the end of May.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
May 10, 2024 09:42 ET (13:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk